kalydeco

Swiss trademark · 635207 · Combined mark · In force

The mark kalydeco as registered

Register entry

Registration number
635207
Application number
56890/2012
Status
In force
Type
Combined mark
As registered
kalydeco ((fig.))
Filed
Jun 5, 2012
Registered
Oct 15, 2012
Published
Oct 15, 2012
Protected until
Jun 5, 2032
Priority
31.03.2012 US
Remarks
Teilpriorität. Details siehe Aktenheft.
Language of procedure
German
Vienna classes
24.17.01, 24.17.02, 26.07.04, 26.11.02, 26.11.09, 26.11.12
Source
Swissreg

Goods and services

Pharmaceuticals

Pharmazeutische Erzeugnisse; pharmazeutische Erzeugnisse für die Behandlung von zystischer Fibrose.

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 25, 2022

    Renewed

    Published in Swissreg on 25.04.2022

  2. Feb 1, 2018

    Agent entered

    Representative
    FRORIEP AG, Bellerivestrasse 201, Postfach, 8034 Zürich → Walder Wyss AG, Seefeldstrasse 123, Postfach 1236, 8034 Zürich

    Published in Swissreg on 01.02.2018

  3. Aug 10, 2016

    Agent’s address changed

    Representative
    FRORIEP, Bellerivestrasse 201, 8034 Zürich → FRORIEP AG, Bellerivestrasse 201, Postfach, 8034 Zürich

    Published in Swissreg on 10.08.2016

  4. Apr 4, 2014

    Holder’s address changed

    Owner
    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, MA 02139-4242, Cambridge, USA → Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston MA 02110, USA

    Published in Swissreg on 04.04.2014

  5. Dec 3, 2013

    Agent’s address changed

    Representative
    Froriep Renggli, Bellerivestrasse 201, 8034 Zürich → FRORIEP, Bellerivestrasse 201, 8034 Zürich

    Published in Swissreg on 03.12.2013

  6. Oct 15, 2012

    Registered

    Published in Swissreg on 15.10.2012

Parties

The register names each party by name and address. A party is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.